[ad_1]
Here’s how much the companies that publish their financial results earn:
Top Winners: Pfizer and BioNTech
The American company Pfizer and the German company BioNTech have gained an advantage over their competitors, since last year they were the first in the Western world to announce the positive results of their vaccine clinical trials.
They were also the first to receive permission from US and European Union (EU) regulators to market their vaccine.
Pfizer made more than its competitors, shrinking $ 10.8 billion in the first half of this year. USD (9.2 billion euros).
The American company has also improved its forecasts for 2021 and now expects its sales to reach 33.5 billion dollars this year. AMERICAN DOLLAR.
BioNTech, meanwhile, reported revenues of $ 7.3 billion in the first half. euros. By the way, the coronavirus vaccine is the only product that the company sells.
BioNTech estimates that vaccine revenue will reach $ 15.9 billion this year. euros. His previous forecast was much less than $ 9.8 billion. euros.
“Modern”
As with BioNTech, the COVID vaccine is the only product released by the American startup Moderna.
Moderna’s turnover in the first half of this year reached 5.9 billion. And the company expects its vaccine revenue to reach $ 20 billion this year. AMERICAN DOLLAR.
AstraZeneca and Johnson & Johnson are falling behind
The vaccines of the British pharmaceutical giant AstraZeneca and the American company Johnson & Johnson were approved in the European Union later than their competitors.
The AstraZeneca vaccine is one of the most popular vaccines in the world and is widely used in various parts of the world, but it has not yet been approved in the United States.
And the Johnson & Johnson vaccine, developed by the company’s Belgian subsidiary, Janssen, has the advantage of requiring only one vaccine to gain immunity, and not two vaccines like its competitors.
Both companies have promised to sell their vaccines during the pandemic at a cost, which means they won’t make a profit from them.
The companies’ vaccines are cheaper than those from Pfizer / BioNTech and Moderna, and this is reflected in their revenue figures.
AstraZeneca COVID-19 vaccine sales reached 1.2 billion in the first half of this year. AMERICAN DOLLAR.
J&J reported 264 million USD sales and is expected to reach $ 2.5 billion for the full year. AMERICAN DOLLAR. AstraZeneca did not provide such a detailed annual forecast.
[ad_2]
